A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside (Monofer) and Iron Sucrose in Subjects With Iron Deficiency Anemia (Ferwon IDA)
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Iron isomaltoside 1000 (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms FERWON IDA
- Sponsors Pharmacosmos
- 14 Mar 2018 Planned End Date changed from 1 Oct 2020 to 1 Oct 2018.
- 14 Mar 2018 Planned primary completion date changed from 1 May 2020 to 1 Oct 2018.
- 02 Nov 2016 Status changed from not yet recruiting to recruiting.